PIRCHE-II: an algorithm to predict indirectly recognizable HLA epitopes in solid organ transplantation

• Published in: Immunogenetics (New York) Vol. 72; no. 1-2; pp. 119 - 129
• Main Authors: Geneugelijk, Kirsten, Spierings, Eric
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.02.2020; Springer Nature B.V
• Subjects: Algorithms; Allergology; Antigens; Biomedical and Life Sciences; Biomedicine; Cell Biology; Computational Biology - methods; Computer simulation; databases and bioinformatics in Immunogenetics; Epitopes; Epitopes - immunology; Gene Function; Graft Rejection - immunology; Graft Survival - immunology; Histocompatibility - immunology; Histocompatibility antigen HLA; Histocompatibility Testing - methods; HLA Antigens - genetics; HLA Antigens - immunology; Human Genetics; Humans; Immunology; Indigent care; Leukocytes; Nomenclature; Organ Transplantation - methods; Review; Risk Factors; Tissue and Organ Procurement; Tissue Donors; Transplantation; Xenotransplantation; Matching; PIRCHE-II; Transplantation; Epitopes; Solid organ transplantation; HLA; Histocompatibility
• ISSN: 0093-7711; 1432-1211; 1432-1211
• DOI: 10.1007/s00251-019-01140-x

Human leukocyte antigen (HLA) mismatches between donors and recipients may lead to alloreactivity after solid organ transplantation. Over the last few decades, our knowledge of the complexity of the HLA system has dramatically increased, as numerous new HLA alleles have been identified. As a result, the likelihood of alloreactive responses towards HLA mismatches after solid organ transplantation cannot easily be assessed. Algorithms are promising solutions to estimate the risk for alloreactivity after solid organ transplantation. In this review, we show that the recently developed PIRCHE-II (Predicted Indirectly ReCognizable HLA Epitopes) algorithm can be used to minimize alloreactivity towards HLA mismatches. Together with the use of other algorithms and simulation approaches, the PIRCHE-II algorithm aims for a better estimated alloreactive risk for individual patients and eventually an improved graft survival after solid organ transplantation.